Pharmacy discounts on generic medicines in France: Is there room for further efficiency savings?

Current Medical Research and Opinion

Volumn 23, Issue 10, 2007, Pages 2467-2476

  Kanavos, Panos ^a   Taylor, David ^b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cost sharing; Discounts; Drug policy; France; Generics; Insurance; Reference pricing

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; GENERIC DRUG; LISINOPRIL; MESALAZINE; METFORMIN; METHYLPHENIDATE; OMEPRAZOLE; PAROXETINE; SALBUTAMOL; SIMVASTATIN;

ARTICLE; CONFIDENTIALITY; CONTROLLED STUDY; DRUG COST; DRUG MANUFACTURE; FRANCE; HUMAN; PILOT STUDY; PROSPECTIVE PRICING; QUESTIONNAIRE;

COST SAVINGS; DRUGS, GENERIC; FRANCE; PHARMACIES; PILOT PROJECTS;

EID: 35648935088     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X219571     Document Type: Article

References (14)

1. Mossialos E, Dixon A, Figueras J, Kutzin J (eds.). Funding Health Care: Options for Europe. European Observatory on Health Care Systems. Buckingham: Open University Press, 2002
2. Simoens S, De Coster S. Sustaining Generic Medicines Markets in Europe. Research Centre for Pharmaceutical Care and Pharmaco-Economics, Catholic University of Leuven, 2006
3. Sandier S, Paris V, Polton D. Health care systems in transition: France. European Observatory on Health Systems and Policies, 2004. Available from: www.euro.who.int/document/e83126.pdf [Last accessed 8 November 2006]
4. Kanavos P, Gemmill MG. Pharmaceutical Pricing and Reimbursement in Europe. London: Informa Publishing, 2005
5. Le Pen, C. Drug pricing and reimbursement in France. Pharmacoeconomics 1996;10(Suppl. 2):26-36
6. Le Pen C. Substitution générique et prescription dans le répertoire (Generic substitution and prescribing practices in the off-patent market). University of Paris-Dauphine: Paris, 2005
7. Comité économique des produits de santé (CEPS). Accord cadre entre le Comité économique des produits de santé et les entreprises du médicament pour la période 2003-2006. Available from: www.sante.gouv.fr/htm/dossiers/accord_med/contenu.htm [Last accessed 8 November 2006]
8. Le Monde. Les pharmaciens, cible de choix des laboratoires'. Paris, 31 October, 2003
9. Kanavos P. Do generics offer significant savings to the UK NHS? Curr Med Res Opin 2006;23:105-16
10. Caves RE, Whinston ME, Hurwitz MA. Patent expiration, entry and competition in the United States pharmaceutical industry: an exploratory analysis. Brookings Papers on Economic Activity: Microeconomics 1991. Washington: Brookings Institute, 1991: 1-48
11. Grabowski H, Vernon J. Brand loyalty and price competition in pharmaceuticals after the 1984 Drug Act', Journal of Law and Economics 1992;35:331-50
12. Garattini L, Ghislandi S. Off-patent drugs in Italy. A short sighted view? Eur J Health Econ 2006;7:79-83
13. Ricketts M. The economics of business enterprise: New approaches to the firm. Brighton: Wheatsheaf Books, 1987
14. Direction de la Recherche des Etudes de l'Evaluation et des Statistiques (DREES). Les Pharmaciens en France. Situation démographique et trajectoires professionnelles. Études et Résultats, Numéro 437, Octobre. Paris: Ministère de la Santé et des Solidarités, 2005